The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Anti-Cancer Drug Design

• Publication date

  2001-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 12049478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.

  1999cited by this paper
• Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.

  1999cited by this paper
• Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia.

  1998cited by this paper
• Tumor cell cytotoxicity of a novel metal chelator.

  1998cited by this paper
• Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities

  1997cited by this paper
• The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells.

  1997cited by this paper
• Transferrin receptor‐independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression

  1996cited by this paper
• The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.

  1995cited by this paper
• The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.

  1994cited by this paper
• Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake

  1994cited by this paper
• The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.

  1994cited by this paper
• Effect of desferrioxamine and hydroxypyridones on hemopoietic progenitors and neuroectodermal tumor cells

  1994cited by this paper
• A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.

  1993cited by this paper
• Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.

  1993cited by this paper
• Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines.

  1993cited by this paper
• Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic

  1992cited by this paper
• Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate.

  1992cited by this paper
• Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.

  1991cited by this paper
• The uptake of inorganic iron complexes by human melanoma cells.

  1991cited by this paper
• Gene expression in clonally derived cell lines produced by in vitro transformation of rat fetal hepatocytes: isolation of cell lines which retain liver-specific markers.

  1990cited by this paper
• The uptake of iron and transferrin by the human malignant melanoma cell.

  1990cited by this paper
• Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor.

  1990cited by this paper
• Differential effects of liposome-entrapped desferrioxamine on proliferation and erythroid differentiation of murine erythroleukemic Friend cells.

  1989cited by this paper
• Transformation of cultured fetal rat liver cells by MDAB and phenobarbital. Morphological, biochemical and immunocytochemical characterization of cell lines.

  1989cited by this paper
• Modulation of the transferrin receptor during DMSO-induced differentiation in HL-60 cells.

  1988cited by this paper
• Deferoxamine inhibition of human neuroblastoma viability and proliferation.

  1988cited by this paper
• Mechanism of antineuroblastoma activity of deferoxamine in vitro.

  1988cited by this paper
• In vitro and in vivo effects of deferoxamine in neonatal acute leukemia.

  1987cited by this paper
• Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.

  1987cited by this paper
• Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells

  1987cited by this paper
• Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells.

  1987cited by this paper
• Iron uptake and metabolism by hepatocytes.

  1986cited by this paper
• The mechanisms of iron uptake by fetal rat hepatocytes in culture

  1986cited by this paper
• Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.

  1985cited by this paper
• Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody.

  1985cited by this paper
• Temperature-sensitive adult liver cell line dependent on glucocorticoid for differentiation

  1983cited by this paper
• TEMPERATURE‐SENSITIVE FETAL LIVER CELLS: A MODEL FOR HEPATOCELLULAR DIFFERENTIATION

  1983cited by this paper
• Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide.

  1983cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents.

  1979cited by this paper
• Mobilization of iron from reticulocytes

  1979cited by this paper
• The Role of Endocytosis in Transferrin Uptake by Reticulocytes and Bone Marrow Cells

  1977cited by this paper
• Relation of Oxygen and Temperature in the Preservation of Tissues by Refrigeration

  1949cited by this paper

• New iron(III) complexes with 2-formylpyridine thiosemicarbazones: Synthetic aspects, structural and spectral analyses and cytotoxicity screening against MCF-7 human cancer cells

  2023cites this paper
• In vitro anti-trypanosomal effects of selected phenolic acids on Trypanosoma brucei

  2019cites this paper
• Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies

  2019cites this paper
• Recent advances in iron complexes as potential anticancer agents

  2016cites this paper
• Cellular iron homeostasis and therapeutic implications of iron chelators in cancer.

  2014cites this paper
• checkpoint kinases, and sensitizes cells to ionizing radiation Tachpyridine, a metal chelator, induces G2 cell cycle arrest, activates

  2013cites this paper
• SYNTEZA I AKTYWNOŚĆ BIOLOGICZNA NOWYCH ANALOGÓW TIOSEMIKARBAZONOWYCH CHELATORÓW ŻELAZA

  2013cites this paper
• New insights into pattern recognition receptors and their ligands in gynecologic pathologies.

  2011cites this paper
• Iron: an emerging factor in colorectal carcinogenesis.

  2010cites this paper
• Malaria and iron: history and review

  2009cites this paper
• Synthetic and natural iron chelators: therapeutic potential and clinical use.

  2009cites this paper
• 3-Hydroxy-2-(5-hydroxypentyl)-4H-chromen-4-one: a bidentate or tridentate iron(III) ligand?

  2006cites this paper
• Cell Permeable Iron Chelators as Potential Cancer Chemotherapeutic Agents

  2005cites this paper
• Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.

  2005cites this paper
• Highly cytotoxic iron(II) complexes with pentadentate pyridyl ligands as a new class of anti-tumor agents.

  2005cites this paper
• The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

  2005cites this paper
• (Bubalus bubalis bubalis - Simpson, 1945)

  2004cites this paper
• Activite antioxydante et de piegeage de radicaux d'analogues synthetiques de desferrithiocine

  2003cites this paper
• Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.

  2003cites this paper
• The role of iron chelation in cancer therapy.

  2003cites this paper